ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1319

Prognostic Utility of Metacarpal Bone Mineral Density Measurement in Patients with Recent-onset Arthritis by Assessment of Radiographic Progression at 2-year Follow Up

Irene Maria Llorente Cubas1, Ana Maria Fernandez Ortiz2, Jesus Alberto Garcia Vadillo1, Jose ivorra Cortes3, Luis Rodriguez-Rodriguez4, Rosario Garcia-Vicuña5, Santos Castañeda6, Isidoro Gonzalez1 and Ana M Ortiz1, 1Hospital Universitario de La Princesa, Madrid, Spain, 2Hospital Universitario de Badajoz, Badajoz, Spain, 3Hospital Universitario de La Fe, València, Spain, 4Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, 5Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 6Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain

Meeting: ACR Convergence 2022

Keywords: Dual energy x-ray absorptiometry (DEXA), osteoporosis, prognostic factors, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Rheumatoid arthritis (RA) and osteoporosis (OP) have a complex interplay in terms of pathogenic mechanisms. In this regard, radiogrammetry (DXR) of the hand, a technique that measures the bone mineral density (BMD) at the central metacarpals (MC) , is associated with a worse prognosis in patients with RA (1). However, DXR is an expensive technique, and not very accessible in our environment. Our group demonstrated an excellent reproducibility of the MC measurement by DXA (2) and good correlation between BMD measurements obtained by DXR and DXA (3).

Objective: To evaluate if baseline BMD of the non dominant MC measured by DXA can be used as a prognostic marker, resembling DXR, in patients with early arthritis (EA).

Methods: A total of 378 subjects from the PEARL (Princesa Early Arthritis Register Longitudinal) study underwent DXA measurement of the 2nd to 4th MC’s diaphyseal area of the non dominant hand (Hologic 4500®). In PEARL sociodemographic, clinical and laboratory parameters, therapeutic data and radiographic findings are collected by protocol. Radiographic progression was evaluated in hands by a blind expert rheumatologist assessing the erosion scale of modified SvdH index in both the baseline and two year follow-up visit. To study the predictive value of MC baseline BMD by DXA, two multivariate models were fitted using generalized linear models with Stata 14.0 for Windows (Stata Corp LP, College Station, TX, USA). The dependent variables were remission (SDAI< 3.3) and radiographic progression after two 2 years of follow-up. Both models were adjusted by the classic variables that affect BMD such as age, sex and body mass index (BMI), cumulative DMARD treatment and baseline disease activity for the remission model.

Results: After adjustment by age, sex and BMI: a) those patients at remission tended to show higher baseline MC’s BMD by DXA (p=0.328); and b) those patients with higher radiographic progression had significantly lower baseline MC’s BMD as shown in Figure 1(p=0.001).

Conclusion: In our registry of patients with EA, we have detected that a lower basal BMD in the diaphysis of the central MC bones, assessed by DXA, is associated with greater radiographic progression at 2 years of follow-up after adjusting for the main factors influencing BMD. Therefore, we could conclude that a low initial bone mass could constitute a poor prognostic factor in patients with EA.

References:
1. Haugeberg G, Lodder MC, Lems WF, Uhlig T, Ørstavik RE, Dijkmans B a. C, et al. Ann Rheum Dis october 2004;63(10):1331-4.
2. Llorente I, Merino L, Escolano E, Quintanilla DM, García-Vadillo JA, González- Álvaro I, et al. C Clin J Densitom 2020;23(4):678-84
3. Ann Rheum Dis, volumen 78, supplement 2, year 2019, page A942

Supporting image 1

Correlation of mean BMD of 2_4th MC bones with radiographyc progression assesed by the modified SvdH radiological index at 2 years, after adjusting for age, sex and BMI, calculated using Stata margins command base don the data obtained from multivariate analysis.


Disclosures: I. Llorente Cubas, None; A. Fernandez Ortiz, None; J. Garcia Vadillo, None; J. ivorra Cortes, None; L. Rodriguez-Rodriguez, None; R. Garcia-Vicuña, Novartis, Sanofi, Merck/MSD, Bristol-Myers Squibb(BMS), Eli Lilly, UCB, Janssen, Sandoz, Pfizer, Biogen; S. Castañeda, Roche; I. Gonzalez, Gebro Pharma; A. Ortiz, None.

To cite this abstract in AMA style:

Llorente Cubas I, Fernandez Ortiz A, Garcia Vadillo J, ivorra Cortes J, Rodriguez-Rodriguez L, Garcia-Vicuña R, Castañeda S, Gonzalez I, Ortiz A. Prognostic Utility of Metacarpal Bone Mineral Density Measurement in Patients with Recent-onset Arthritis by Assessment of Radiographic Progression at 2-year Follow Up [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/prognostic-utility-of-metacarpal-bone-mineral-density-measurement-in-patients-with-recent-onset-arthritis-by-assessment-of-radiographic-progression-at-2-year-follow-up/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prognostic-utility-of-metacarpal-bone-mineral-density-measurement-in-patients-with-recent-onset-arthritis-by-assessment-of-radiographic-progression-at-2-year-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology